Xu Tian-min, Xin Ying, Cui Man-hua, Jiang Xin, Gu Li-ping
Department of Obstetrics and Gynaecology, Second Hospital of Jilin University, Changchun 130041, China.
Chin Med J (Engl). 2007 Apr 5;120(7):584-8.
Ginsenoside Rg3, the main component isolated from ginseng, inhibits some kinds of tumour growth and angiogenesis. The combination of low dose chemotherapy and antiangiogenesis inhibitors suppresses growth of experimental tumours more effectively than conventional therapy. The effect of this combination on ovarian cancer remains to be evaluated. Therefore, we investigated the synergism of ginsenoside Rg3 and cyclophosphamide (CTX) on growth and angiogenesis of human ovarian cancer.
Twenty-eight female athymic mice were divided randomly into 4 groups of 7: ginsenoside Rg3, CTX, ginsenoside Rg3 and CTX combination and control, after being transplanted with ovarian cancer cells (SKOV-3). The mice were given intraperitoneal injection of ginsenoside Rg3 and CTX for the 10 days following inoculation of SKOV-3 cells. The life quality and number of living days of mice were recorded. The size of tumour, tumour inhibitive rate, life elongation rate, proliferating cell nuclear antigen labelling index (PCNALI), expression of vascular endothelial cell growth factor (VEGF) and microvessel density (MVD) of the tumour tissues were estimated.
Life quality of mice in ginsenoside Rg3 and combined treatment groups were better and number of living days longer than control. Average tumour weights of each treated group were less than control and there was no significant difference among the treated groups. PCNALI of treated groups was lower than control. The MVD value and VEGF expression in treated groups were significantly lower than control and the MVD values of ginsenoside Rg3 and combined treatment groups were lower than that of CTX group.
Ginsenoside Rg3 significantly inhibited growth and angiogenesis of ovarian cancer when used alone or combined with CTX. Ginsenoside Rg3 and CTX combination reinforced the antitumour effect each other and improved the living quality and survival time of mice with tumour.
人参皂苷Rg3是从人参中分离出的主要成分，可抑制某些肿瘤的生长和血管生成。低剂量化疗与抗血管生成抑制剂联合使用比传统疗法更有效地抑制实验性肿瘤的生长。这种联合疗法对卵巢癌的疗效仍有待评估。因此，我们研究了人参皂苷Rg3与环磷酰胺（CTX）对人卵巢癌生长和血管生成的协同作用。
28只雌性无胸腺小鼠在接种卵巢癌细胞（SKOV-3）后随机分为4组，每组7只：人参皂苷Rg3组、CTX组、人参皂苷Rg3与CTX联合组和对照组。在接种SKOV-3细胞后的10天内，给小鼠腹腔注射人参皂苷Rg3和CTX。记录小鼠的生活质量和存活天数。估计肿瘤大小、肿瘤抑制率、生命延长率、增殖细胞核抗原标记指数（PCNALI）、肿瘤组织中血管内皮细胞生长因子（VEGF）的表达和微血管密度（MVD）。
人参皂苷Rg3组和联合治疗组小鼠的生活质量较好，存活天数比对照组长。各治疗组的平均肿瘤重量均低于对照组，各治疗组之间无显著差异。治疗组的PCNALI低于对照组。治疗组的MVD值和VEGF表达明显低于对照组，人参皂苷Rg3组和联合治疗组的MVD值低于CTX组。
人参皂苷Rg3单独使用或与CTX联合使用时，均能显著抑制卵巢癌的生长和血管生成。人参皂苷Rg3与CTX联合使用可相互增强抗肿瘤作用，提高荷瘤小鼠的生活质量和生存时间。
Zotero 插件